Sykes M, Sachs D H
Transplantation Biology Research Center, Surgical Service, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA.
Philos Trans R Soc Lond B Biol Sci. 2001 May 29;356(1409):707-26. doi: 10.1098/rstb.2001.0853.
Induction of mixed chimerism has the potential to overcome the current limitations of transplantation, namely chronic rejection, complications of immunosuppressive therapy and the need for xenografts to overcome the current shortage of allogeneic organs. Successful achievement of mixed chimerism had been shown to tolerize T cells, B cells and possibly natural killer cells, the lymphocyte subsets that pose major barriers to allogeneic and xenogeneic transplants. Current understanding of the mechanisms involved in tolerization of each cell type is reviewed. Considerable advances have been made in reducing the potential toxicity of conditioning regimens required for the induction of mixed chimerism in rodent models, and translation of these strategies to large animal models and in a patient are important advances toward more widespread clinical application of the mixed chimerism approach for tolerance induction.
诱导混合嵌合体有潜力克服当前移植的局限性,即慢性排斥反应、免疫抑制治疗的并发症以及为克服目前同种异体器官短缺而对异种移植物的需求。已证明成功实现混合嵌合体可使T细胞、B细胞以及可能的自然杀伤细胞耐受,这些淋巴细胞亚群是同种异体和异种移植的主要障碍。本文综述了目前对每种细胞类型耐受机制的理解。在降低啮齿动物模型中诱导混合嵌合体所需预处理方案的潜在毒性方面已取得了相当大的进展,将这些策略转化到大动物模型和患者身上是朝着更广泛地临床应用混合嵌合体方法诱导耐受迈出的重要一步。